Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib in Advanced/Metastatic Neuroendocrine Tumors
NCT02259725Phase 2Completed
- Sponsor
- University of Southern California
- Start
- Aug 2016
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of regorafenib in Neuroendocrine Neoplasm (NEN), sponsored by University of Southern California. Started Aug 2016; status: completed.
02
Drugs
regorafenib
03
Conditions
Neuroendocrine Neoplasm (NEN)
Beyond the preview
Go deeper on NCT02259725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02259725.